SA114. Lurasidone for the Treatment of Adolescent Patients With Schizophrenia: Effect on PANSS Subscales

Abstract

Background: Lurasidone is an atypical antipsychotic agent that has dem-onstrated effcacy in the treatment of adults with schizophrenia in the dose range of 40-160 mg/d. The objective of this randomized, double-blind, placebo-controlled study was to evaluate the acute effcacy and safety of lurasidone in adolescent patients with schizophrenia. Methods: Adolescents (13-17 years old) diagnosed with schizophrenia were randomly assigned to 6 weeks of double-blind treatment with fxed-dose lurasidone 40 mg/d, 80 mg/d, or placebo. Changes from baseline to Week 6 in PANSS total and subscale (positive, negative, general psychopathology, excitability) scores were evaluated using mixed-model, repeated-measures analysis. Treatment response was defned as ≥20% reduction from baseline in PANSS total score at Week 6 and was analyzed using a logistic regression model with last observation carried forward (LOCF) approach. Results: A total of 326 patients (mean age, 15.4 years) were randomized and received lurasidone 40 mg/d (N = 108), 80 mg/d (N = 106), or placebo (N = 112). The PANSS total score at Week 6 demonstrated a placebo-adjusted, least-squares (LS) mean improvement of-8.0 (P